APR 14, 2016 09:00 AM PDT
Primary Hyperaldosteronism: From A to Z
SPONSORED BY: DiaSorin
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
11 58 4672

Speakers:
  • Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology
    Biography
      Dr. Williams is an Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension.  He has dedicated his research efforts to unravelling the intricate relationship between genetics and environment with respect to individual susceptibility to cardiometabolic disease.  He has over 40 original publications describing the physiologic and pathologic interplay of renin-angiotensin-aldosterone system activity and dietary salt intake in hypertension, insulin resistance, heart disease, and obesity.  His work is funded through National Institutes of Health, industry, and private foundation support.
       
      Dr. Williams is an active program developer, course director, and mentor for the Harvard Medical School's Scholars in Clinical Research Program, which is a Master's degree granting program designed to train the upcoming generation of patient-oriented physician scientists.  He is also an Associate Editor of the journal Metabolism, and serves on the Board of Directors for the Association for Patient-oriented Research and for the Association for Clinical and Translational Science.

    Abstract:
    9:00AM PT, 11:00AM CT, 12:00PM ET

    The prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%.  It is considered a secondary form of hypertension caused by inappropriate secretion of aldosterone and activation of the mineralocorticoid receptor.  As such, it is a highly treatable and potentially curable form of hypertension.  This webinar will review the prevalence, pathophysiology, screening and diagnostic studies, and treatment options for patients with primary hyperaldosteronism so that the Practitioner can accurately screen and identify cases.

    Learning objectives:

    1.  Understand the prevalence, pathophysiology and diagnostic studies for patients with primary hyperaldosteronism.
     
    2.  Be able to identify screening and treatment options for patients with primary hyperaldoseronism.
     
     

    Show Resources
    Loading Comments...